Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population

What are the health economic consequences of comprehensive genomic profiling (CGP) in an advanced pancancer population?This economic evaluation with 814 participants found that diagnostic costs amount to €2816 to identify 1 patient with an actionable target to €14 249 to identify 1 patient receiving a CGP-matched treatment. Adopting a conceptual willingness-to-pay threshold of €5000 per matched treatment, a CGP cost reduction to €1250 combined with an increased uptake of molecular tumor board recommendations to 47% was required to achieve a positive net monetary benefit.These results suggest that substantial diagnostic costs made to match 1 CGP-informed treatment can be reduced most effectively by lowering diagnostic costs and increasing uptake of molecular tumor board recommendations.

Corresponding Author: Valesca P. Retèl, PhD, Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands (v.retel@nki.nl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.